Perrigo (PRGO) Non-Current Assets (2013 - 2026)
Perrigo's (PRGO) quarterly Non-Current Assets came in at $5.3 billion in Q1 2026, down 27.06% year-on-year from $7.2 billion in Q1 2025, and down 8.14% on a QoQ basis from $5.7 billion in Q4 2025.
Perrigo (PRGO) Non-Current Assets (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Non-Current Assets data on file, last reported at $5.3 billion in Q1 2026.
- On a quarterly basis, Non-Current Assets fell 27.06% year-over-year to $5.3 billion in Q1 2026; TTM through Mar 2026 was $5.3 billion, a 27.06% decrease from a year earlier, with the FY2025 full-year figure at $5.7 billion, down 19.93% from the prior year.
- Non-Current Assets for Q1 2026 stood at $5.3 billion, down from $5.7 billion in the prior quarter.
- Over the last five years, Non-Current Assets for PRGO reached as high as $8.3 billion in Q4 2022 and fell as low as $5.3 billion in Q1 2026.
- Historically, Non-Current Assets has averaged $7.4 billion across 5 years, with a median of $7.5 billion in 2024.
- Across the five-year window, Non-Current Assets grew 27.27% in 2023 and retreated 27.06% in 2026, its largest moves.
- Year by year, Non-Current Assets stood at $8.3 billion in 2022, then declined by 3.87% to $8.0 billion in 2023, then declined by 10.16% to $7.2 billion in 2024, then retreated by 19.93% to $5.7 billion in 2025, then slipped by 8.14% to $5.3 billion in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $5.3 billion in Q1 2026, $5.7 billion in Q4 2025, and $7.2 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | 5.27 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 5.27 Bn |
| Dec 31, 2025 | 5.74 Bn |
| Sep 27, 2025 | 7.20 Bn |
| Jun 28, 2025 | 7.48 Bn |
| Mar 29, 2025 | 7.23 Bn |
| Dec 31, 2024 | 7.17 Bn |
| Sep 28, 2024 | 7.50 Bn |
| Jun 29, 2024 | 7.44 Bn |
| Mar 30, 2024 | 7.83 Bn |
| Dec 31, 2023 | 7.98 Bn |
| Sep 30, 2023 | 7.99 Bn |
| Jul 1, 2023 | 8.19 Bn |
| Apr 1, 2023 | 8.21 Bn |
| Dec 31, 2022 | 8.30 Bn |
| Oct 1, 2022 | 8.09 Bn |
| Jul 2, 2022 | 8.27 Bn |
| Apr 2, 2022 | 6.45 Bn |
| Dec 31, 2021 | 6.57 Bn |
| Oct 2, 2021 | 6.69 Bn |
| Jul 3, 2021 | 6.81 Bn |